[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"basilar-artery-occlusion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:basilar-artery-occlusion":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,47,74,99,136,160,182,204,230,255,278,299,327],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100644695","endovascular-therapy-for-acute-basilar-artery-occlusion-with-large-ischemic-core-100644695",false,"NCT07672795","Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core","Efficacy and Safety of Endovascular Therapy for Acute Basilar Artery Occlusion With Large Ischemic Core: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Clinical symptoms or imaging findings suggestive of acute posterior circulation ischemic stroke.\n* Basilar artery occlusion confirmed by CTA, MRA, or DSA.\n* Posterior circulation ASPECTS \\\u003C7 on CT, CTA source images, or MRI-DWI.\n* Age 18 to 80 years.\n* Time from symptom onset or last known well to randomization within 24 hours.\n* Written informed consent obtained from the patient or legally authorized representative.\n* Baseline NIHSS score ≥6 before randomization.\n\nExclusion Criteria:\n\n* Pre-stroke modified Rankin Scale score ≥3.\n* Pregnancy or lactation.\n* Known allergy to contrast agents or nickel-titanium alloy.\n* Current participation in another clinical trial.\n* Systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg that cannot be controlled with antihypertensive therapy.\n* Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, or current oral anticoagulant use with INR \\>1.7.\n* Blood glucose \\\u003C50 mg\u002FdL or \\>400 mg\u002FdL, platelet count \\\u003C50 × 10\\^9\u002FL, or hematocrit \\\u003C25%.\n* Life expectancy less than 1 year.\n* Inability to complete 90-day follow-up.\n* Definite history of cerebral vasculitis.\n* Pre-existing neurological or psychiatric disorder that may interfere with neurological or functional assessment.\n* Intracranial hemorrhage on CT or MRI, except for cerebral microbleeds \\\u003C5 mm on MRI.\n* Vascular tortuosity, anatomical variation, or arterial dissection on CTA, MRA, or DSA that precludes endovascular treatment.\n* Intracranial tumor, except for small meningioma.","ALL","18 Years",{"count":19,"type":20},256,"ESTIMATED","INTERVENTIONAL",[23],"NA","Acute basilar artery occlusion is associated with high mortality and severe disability. Previous randomized trials have demonstrated the benefit of endovascular therapy in selected patients with basilar artery occlusion; however, patients with large ischemic core, commonly defined by low posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS), remain underrepresented and the benefit-risk profile of endovascular therapy in this subgroup is uncertain.\n\nThis prospective, multicenter, randomized, open-label, blinded-endpoint trial will evaluate the efficacy and safety of endovascular therapy plus best medical management compared with best medical management alone in patients with acute basilar artery occlusion within 24 hours from symptom onset or last known well and pc-ASPECTS \\\u003C7. Eligible participants will be randomized in a 1:1 ratio to receive endovascular therapy plus best medical management or best medical management alone. The primary outcome is favorable functional outcome, defined as a modified Rankin Scale score of 0 to 3 at 90 days.",[26,27,28],"Acute Ischemic Stroke","Basilar Artery Occlusion","Large Ischemic Core",[30,31,32,33,34],"Basilar artery occlusion","Endovascular therapy","Mechanical thrombectomy","Posterior circulation stroke","Large ischemic core","NOT_YET_RECRUITING","2026-06-30",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":20},"2026-08-01",{"date":43,"type":20},"2029-12-31",{"name":45,"class":46},"The First Affiliated Hospital of University of Science and Technology of China","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":72,"locationsCount":73},"100502806","phase-3-endovascular-thrombectomy-alone-versus-intravenous-thrombolysis-plus-thrombectomy-on-acute-basilar-artery-occlusion-100502806","NCT05827042","Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion","Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Endovascular Thrombectomy on Acute Basilar Artery Occlusion - a Multicenter, Randomized Controlled, Clinical Trial","Inclusion Criteria:\n\n1. Patients presenting with posterior circulation ischemic stroke symptoms due to basilar artery occlusion or vertebral artery occlusions that prevent antegrade flow into the basilar artery;\n2. Time from stroke onset to randomization within 4.5 hours of estimated time of basilar artery occlusion;\n3. Patient's age ≥ 18 years;\n4. Presence of basilar artery or vertebral artery occlusion, confirmed by CT Angiography (CTA), MR Angiography (MRA) or Digital Subtraction Angiography (DSA). In case of vertebral artery occlusion, the occlusion must completely prevent antegrade flow into the basilar artery;\n5. Patients presenting with acute ischemic stroke eligible to receive both endovascular thrombectomy and intravenous thrombolysis using standard criteria;\n6. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥ 10;\n7. The patient or patient's legal representative signs the informed consent form.\n\nExclusion Criteria:\n\n1. CT or MR evidence of intracerebral hemorrhage (the presence of \\\u003C 10 microbleeds is allowed);\n2. Pre-stroke modified Rankin scale (mRS) score ≥ 2;\n3. Posterior circulation Acute Stroke Prognosis Early CT Score (PC-ASPECTS) on CT\u002F CTA-Source Images\\\u003C6; PC-ASPECTS on magnetic resonance imaging-diffusion weighted imaging (MRI-DWI) \\\u003C5;\n4. Pregnant or lactating women;\n5. Allergy to contrast agent or nitinol alloy;\n6. Life expectancy\\\u003C1 year;\n7. CTA\u002FMRA\u002FDSA show vascular tortuosity, anatomical variation or artery dissection, which would make it difficult to perform endovascular treatment;\n8. Participating in other clinical trials;\n9. Systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg, which can not be controlled by antihypertensive drugs;\n10. Genetic or acquired hemorrhagic diathesis, lack of anticoagulant factor; oral anticoagulant with international normalized ratio (INR) \\> 1.7; or novel oral anticoagulant within prior 48 hours;\n11. Blood glucose \\\u003C50 mg\u002Fdl (2.8 mmol\u002FL) or \\>400 mg\u002Fdl (22.2 mmol\u002FL), platelet\\\u003C 100\\*109\u002FL;\n12. Renal insufficiency defined as serum creatinine \\>2.0 mg\u002Fdl (or 176.8 μ mol\u002Fl), glomerular filtration rate \\\u003C30 mL\u002Fmin, need for hemodialysis or peritoneal dialysis;\n13. Patients who cannot complete 90-day follow-up (such as patients without fixed residence, overseas patients, etc);\n14. The patient has acute ischemic cerebral infarction within 3 months from randomization;\n15. The patient had a history of or clinical suspicion for cerebral vasculitis or infectious endocarditis;\n16. The patient has nervous system disease or mental disorder before stroke onset, which may affect the assessment of their condition;\n17. CT or MR examination showed large cerebellar infarction with obvious space occupying effect and compression of the fourth ventricle;\n18. Patients with extensive bilateral thalamic or extensive bilateral brainstem infarction on CT or MR examination;\n19. CTA\u002FMRA\u002FDSA show both anterior and posterior circulation large vessel occlusion;\n20. Patients with intracranial tumors (except small meningiomas);\n21. Patients who received intravenous thrombolytics treatment before the randomization.",{"count":55,"type":20},338,[57],"PHASE3","To assess the effect of endovascular thrombectomy alone compared to intravenous thrombolysis plus endovascular thrombectomy in acute basilar artery occlusion patients within 4.5 hours from onset on efficacy and safety outcomes.",[27,60,61],"Acute Cerebrovascular Accident","Stroke Due to Basilar Artery Occlusion",[63,64],"Thrombectomy","thrombolysis","RECRUITING","2026-06-05",{"date":68,"type":39},"2026-06-09",{"date":70,"type":39},"2023-05-09",{"date":36,"type":20},{"name":45,"class":46},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":73},"100523896","efficacy-and-safety-of-endovascular-recanalization-for-acute-basilar-artery-occlusion-with-extended-time-window-angel-bao-100523896","NCT06101667","Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window -- A Multicenter, Prospective, Open-label, Blind Endpoint, Randomized Controlled Trial（ANGEL-BAO）","ANGEL-BAO","Inclusion Criteria:\n\n1. Age≥18 years\n2. Acute basilar artery occlusion confirmed by CTA, MRA, or DSA\n3. Pre-stroke mRS of 0-2\n4. NIHSS score ≥ 10 before randomization\n5. Time interval from symptom onset (or last known well) to randomization within 24-72 hours\n6. Diffusion-weighted imaging(DWI)-based pc-ASPECTS ≥ 6 and Pons-Midbrain Index (PMI) ≤3\n7. Time from completion of DWI imaging to randomization is ≤3 hours\n8. Each patient or their legal representative must provide written informed consent before enrolment\n\nExclusion Criteria:\n\n1. Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization\n2. Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging\n3. CT or MRI evidence of intracranial tumor (except small meningioma and cerebral aneurysm \\\u003C 3mm in diameter)\n4. Known or highly suspected chronic occlusion of basilar artery\n5. History of contraindication for contrast medium (except mild rash)\n6. Current pregnant or breast-feeding\n7. Known to have dementia or psychiatric disease unable to complete neurological assessment and follow-up\n8. Life expectancy is less than 3 months\n9. Enrolled in another drug or device trial or expected to participate in another drug or device treatment trial within the following 3 months.\n10. Any other condition (in the opinion of the site investigator) that inappropriate to participate this study",{"count":83,"type":20},224,[23],"The aim of this study is to assess the efficacy and safety of endovascular treatment versus medical management in patients with acute basilar artery occlusion with extended time window of 24-72 hours from onset.",[26,27],[26,27,88,89],"Extended Time Window","Endovascular Treatment","2026-04-29",{"date":92,"type":39},"2026-05-05",{"date":94,"type":39},"2023-11-16",{"date":96,"type":20},"2027-12-31",{"name":98,"class":46},"Beijing Tiantan Hospital",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100447376","phase-2-extending-the-time-window-for-tenecteplase-by-recanalization-of-basilar-artery-occlusion-in-posterior-circulation-stroke-100447376","NCT05105633","Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke","Extending the Time Window for Tenecteplase by Effective RecanalizatioN of bAsilar Artery occLusion in Patients With POSTerior Circulation Stroke (POST-ETERNAL)","POST-ETERNAL","Inclusion Criteria:\n\n* Patients presenting with posterior circulation ischemic stroke symptoms due to partial or complete basilar artery occlusion within 24 hours from symptom onset (or clinical deterioration\u002Fcoma) or the time the patient was last known to be well.\n* Patient's age is ≥18 years\n* Presence of basilar artery occlusion, proven by CT Angiography or MR Angiography. Basilar artery occlusion is defined as 'potentially retrievable' occlusion at the basilar artery. This can be a partial or complete occlusion.\n* Premorbid mRS ≤3 (independent function or requiring only minor domestic assistance and able to manage alone for at least 1 week).\n* Local legal requirements for consent have been satisfied.\n\nExclusion Criteria:\n\n* Intracerebral hemorrhage (ICH) or other diagnosis (e.g. tumour) identified by baseline imaging.\n* Posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) \\\u003C7 on non-contrast CT, CT Angiography source images or DWI MRI.\n* Significant cerebellar mass effect or acute hydrocephalus.\n* Established frank hypodensity on non-contrast CT indicating subacute infarction.\n* Bilateral extensive brainstem ischemia.\n* Strong suspicion of underlying intracranial atherosclerotic disease (e.g diffuse arterial calcifications, basilar stenosis) or dissection which may require immediate neuro-interventional procedure with intracranial stenting and not benefit from intravenous thrombolysis at investigator's discretion.\n* Pre-stroke mRS of ≥4 (indicating moderate to severe previous disability).\n* Other standard contraindications to intravenous thrombolysis.\n* Contraindication to imaging with contrast agents.\n* Clinically evident pregnant women.\n* Current participation in another research drug treatment protocol.\n* Known terminal illness such that the patients would not be expected to survive a year.\n* Planned withdrawal of care or comfort care measures.\n* Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.",{"count":108,"type":20},688,[110,57],"PHASE2","Patients presenting to the emergency department with an acute ischemic stroke due to basilar artery occlusion within 24 hours of stroke onset will be assessed to determine their eligibility for randomization into the trial. If the patient gives informed consent they will be randomised 50:50 using a central computerised allocation process to either standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg\u002Fkg) or tenecteplase 0.25mg\u002Fkg before undergoing mechanical thrombectomy as required at treating clinician's discretion. The trial is Multi-arm, Multi-stage, prospective, randomised, open-label, blinded endpoint (PROBE) design with seamless phase 2b\u002F3 transition if the intermediate endpoint (recanalization without symptomatic intracerebral hemorrhage) is met in analysis of the first 202 patients. Adaptive sample size re-estimation (Mehta and Pocock) will be performed when 240 patients have completed 3 month follow-up (minimum sample size 320, maximum sample size 688).",[27],[114,115,116,117,118,119,120,121,122,123,124,125,126],"ischemic stroke","basilar artery occlusion","Stroke","Tenecteplase","Tissue Plasminogen Activator","Cerebrovascular Disorders","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Vascular Diseases","Cardiovascular Diseases","Fibrin Modulating Agents","Molecular Mechanisms of Pharmacological Action",{"date":128,"type":39},"2026-05-06",{"date":130,"type":39},"2021-11-29",{"date":132,"type":20},"2029-05",{"name":134,"class":46},"University of Melbourne",17,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":146,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":158,"locationsCount":73},"100608597","phase-4-tenecteplase-before-interhospital-transfer-in-acute-basilar-artery-occlusion-at-45-to-24-hours-100608597","NCT07203625","Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours","Intravenous Tenecteplase Before Interhospital Transfer for Thrombectomy in Acute Basilar Artery Occlusion at 4.5 to 24 Hours","OPTION-2","Inclusion Criteria:\n\n* Age ≥18 years;\n* Patients presenting with posterior circulation ischemic stroke symptoms due to BAO;\n* BAO confirmed by computed tomographic angiography (CTA)\u002F magnetic resonance angiography (MRA);\n* Time from AIS symptom onset to randomization within 4.5-24 hours, stroke onset is defined as the onset of acute symptoms leading to the clinical diagnosis of basilar artery occlusion (BAO) not considering the time of any preceding minor prodromal symptoms (such as isolated vertigo, diplopia or sensory changes) as onset time or, if not known, the time the patient was last known to be well (including wake-up stroke and unwitnessed stroke);\n* Baseline National Institute of Health Stroke Scale (NIHSS) score obtained prior to randomization ≥6;\n* Functionally independent (modified Rankin Scale \\[mRS\\] 0-2) prior to stroke onset;\n* Intended to transfer for thrombectomy. Two paradigms are allowed in this study: (1)transferring patients to ECC (patient transfer); (2)travelling neurointerventionist to nECC (physician transfer);\n* Written informed consent from patients or legally responsible representatives\n\nExclusion Criteria:\n\n* Posterior Circulation Acute Stroke Prognosis Early CT score (PC-ASPECTS) \\\u003C 6 on computed tomography (CT)\u002FCTA-Source Images\u002FMRI with diffusion-weighted imaging (DWI)\n* CT\u002FMR shows evidence of intracranial hemorrhage and tumor (except small meningioma)\n* Complete cerebellar infarct on CT\u002FMRI with significant mass effect and compression of the 4th ventricle\n* Bilateral extensive brainstem infarction on CT\u002FMRI\n* Simultaneous occlusion of both anterior and posterior circulation confirmed by CTA\u002FMRA\u002FDSA (patients with a history of occlusion of anterior circulation more than three months ago can be included)\n* Treatment with a thrombolytic within the last 72 hours or intention to receive intravenous thrombolysis\n* Known hypersensitivity or allergy to any ingredients of Tenecteplase\n* Any other contra-indication for intravenous thrombolysis except for the time criteria\n* Known hereditary or acquired hemorrhagic diathesis\n* Impairment in coagulation due to comorbid disease or anticoagulant use. If on warfarin, international normalized ratio (INR) \\>1.7 or prothrombin time \\>15s; if use of any direct oral anticoagulant within the last 48 hours; if use of heparin\u002Fheparinoid within the last 24 hours\n* Ischemic stroke or myocardial infarction in previous 3 months\n* Previous intracranial hemorrhage, active internal bleeding (gastrointestinal or urinary tract hemorrhage) in previous 3 months\n* Severe, uncontrolled hypertension (systolic blood pressure \\>185mmHg or diastolic blood pressure \\>110mmHg)\n* Baseline blood glucose \\\u003C50mg\u002Fdl or \\>400mg\u002Fdl\n* Baseline platelet count \\\u003C100,000\u002FμL\n* Undergoing hemodialysis or peritoneal dialysis; known severe renal insufficiency with glomerular filtration rate \\\u003C30mL\u002Fmin or serum creatinine \\>220mmol\u002FL (2.5mg\u002FdL)\n* Known severe, life-threatening allergy (more severe than skin rash) to contrast agents\n* Patients with acute stroke within the first 48 hours after percutaneous cardiac, cerebrovascular interventions and major surgery\n* Known diagnosis or clinical suspicion of cerebral vasculitis\n* Known diagnosis or clinical suspicion of endocarditis\n* Pregnancy or lactating;\n* Other serious, advanced or terminal illness with life expectancy less than 6 months\n* Current participation in any investigational study that may confound outcome assessment of the study\n* Any condition that, in the judgement of the investigator, is inappropriate for participation in the trial or could impose hazards to the patient (e.g. inability to understand and\u002For follow the study procedures and\u002For follow-up due to mental disorders, cognitive or emotional disorders)",{"count":145,"type":20},316,[147],"PHASE4","This study is designed to investigate the efficacy and safety of intravenous tenecteplase before interhospital transfer from a non-endovascular capable center(nECC) to an endovascular capable center (ECC) for thrombectomy in patients with acute ischemic stroke (AIS) caused by neuroimaging-confirmed acute basilar artery occlusion (BAO) between 4.5-24 hours of symptom onset.",[26,27],[115,64,151],"interhospital transfer","2026-03-16",{"date":154,"type":39},"2026-03-19",{"date":156,"type":39},"2026-01-20",{"date":96,"type":20},{"name":159,"class":46},"Xuanwu Hospital, Beijing",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":180,"locationsCount":73},"100622931","the-efficacy-and-safety-of-endovascular-treatment-for-acute-mild-basilar-artery-occlusion-100622931","NCT07390032","The Efficacy and Safety of Endovascular Treatment for Acute Mild Basilar Artery Occlusion","The Efficacy and Safety of Endovascular Treatment for Acute Mild Basilar Artery Occlusion: A Multicenter, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age≥18\n2. Acute ischemic stroke in posterior circulation, the time from stroke onset (or finally found normal) to randomization was within 24 hours\n3. Acute basilar artery occlusion confirmed by CTA,MRA,or DSA\n4. NIHSS score≥2 points and\\\u003C10 points from the onset of the disease to before randomization\n5. Posterior circulation large core infarction:NCCT or DWI showed pc-ASPECTS≥6, or Pons-Midbrain Index (PMI)\\\u003C3\n6. No significant functional disability before stroke (mRS≤2 points)\n7. Each patient or their legal representative must provide written informed consent before enrolment\n\nExclusion Criteria:\n\n1. Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization\n2. Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging\n3. Known or highly suspected chronic occlusion of basilar artery\n4. History of contraindication for contrast medium (except mild rash)\n5. CTA\u002FMRA\u002FDSA confirmed occlusion of anterior and posterior circulation\n6. Severe stenosis, arterial dissection, or excessive tortuosity of the extracranial or intracranial segments of the vertebral artery may result in the inability of interventional instruments to be successfully delivered or positioned\n7. Current pregnant or breast-feeding\n8. Refractory hypertension (defined as systolic blood pressure\\>185 mmHg or diastolic blood pressure\\>110 mmHg) that cannot be controlled by drug treatment\n9. Known hereditary or acquired bleeding tendency, lack of coagulation factors, or oral anticoagulants with INR\\>1.5\n10. Blood glucose\\\u003C2.8 or\\>22.2 mmol\u002FL; Platelet count\\\u003C100\\*109\u002FL, serum creatinine\\>2.0 g\u002FL (177 μ mol\u002FL), or glomerular filtration rate\\\u003C30 ml\u002F(min\\*1.73 m2)\n11. Enrolled in another drug or device trial or expected to participate in another drug or device treatment trial within the following 3 months\n12. Acute cerebral infarction occurred within 48 hours after cardio cerebral vascular intervention or major surgery (patients over 48 hours can be included in the group)\n13. Patients whose life expectancy is less than 1 year (such as patients with malignant tumor, advanced cardiopulmonary disease, etc.)\n14. Central nervous system vasculitis has been diagnosed or clinically suspected\n15. Known to have dementia or psychiatric disease unable to complete neurological assessment and follow-up\n16. It is known that patients with dementia or mental illness cannot complete neurological function assessment and follow-up\n17. Any other condition (in the opinion of the site investigator) that inappropriate to participate this study",{"count":168,"type":20},230,[23],"This study assesses the efficacy and safety of endovascular treatment for acute mild basilar artery occlusion within a multicenter, prospective, open-label, endpoint-blinded, randomized controlled clinical trial.",[172,27,89],"Acute Mild Basilar Artery Occlusion",[26,172,27,89],"2026-01-28",{"date":176,"type":39},"2026-02-05",{"date":178,"type":20},"2026-03-01",{"date":43,"type":20},{"name":181,"class":46},"Feng Gao",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":73},"100619521","basilar-artery-occlusion-chinese-endovascular-registry-in-patients-with-large-core-infarct-100619521","NCT07345702","Basilar Artery Occlusion Chinese Endovascular Registry in Patients With Large-Core Infarct","Endovascular Versus Medical Therapy for Acute Large-Core Basilar Artery Occlusion: A Multicenter Retrospective Registry Study (BAOCHE-LC)","BAOCHE-LC","Inclusion Criteria:\n\n1. Age ≥18 years, men or women.\n2. Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA\u002FMRA\u002FDSA.\n3. Time from symptom onset (or last known well) to treatment (endovascular therapy or medical therapy) ≤7 days.\n4. Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 0-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.\n\nExclusion Criteria:\n\n1. Subjects with occlusions in both anterior and posterior circulation.\n2. CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).\n3. Missing key clinical information (e.g., unavailable baseline NIHSS, unclear symptom onset\u002Flast known well time, or missing major treatment information including whether EVT was performed).\n4. Baseline NIHSS score \\\u003C6.\n5. Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.\n6. Missing follow-up outcomes at 90 days.\n7. Any other condition judged by investigators to substantially affect analysis or interpretation.",{"count":191,"type":20},518,"OBSERVATIONAL","This multicenter retrospective registry study evaluates the safety and effectiveness of endovascular therapy versus medical therapy for acute large-core basilar artery occlusion. It also investigates clinical, imaging, and laboratory factors associated with functional outcomes and mortality. Patients are grouped according to the treatment received in routine clinical practice.",[27,195,196],"Ischemic Stroke","Large Core Infarct","2026-01-15",{"date":156,"type":39},{"date":200,"type":20},"2026-01-31",{"date":202,"type":20},"2026-10-31",{"name":159,"class":46},{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":21,"phases":214,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":227,"locationsCount":73},"100599934","evt-in-acute-basilar-artery-occlusion-with-large-infarction-core-100599934","NCT07090941","EVT in Acute Basilar Artery Occlusion With Large Infarction Core","Trial of Endovascular Treatment in Acute Basilar Artery Occlusion Patients With a Large Infarct Core","BOLT","Inclusion Criteria:\n\n* 1\\. Age ≥18 years. 2. Symptoms and signs consistent with basilar artery ischemia. 3. Basilar artery or vertebral artery occlusion confirmed by computed tomography angiography (CTA), magnetic resonance angiography (MRA), digital subtraction angiography (DSA); if vertebral artery occlusion is present, it must completely obstruct blood flow to the basilar artery.\n\n  4\\. POST-NIHSS score ≥10 at randomization. 5. Time from symptom onset to randomization ≤24 hours (symptom onset defined as last known well time).\n\n  6\\. pc-ASPECTS of 3-5 on CT\u002FMRI (for patients aged \\\u003C80 years) or pc-ASPECTS of 3-7 (for patients aged ≥80 years).\n\n  7\\. Willingness of the patient or legally authorized representative to comply with protocol requirements and data collection procedures, with documented informed consent.\n\nExclusion Criteria:\n\n* 1\\. Pre-stroke modified Rankin Scale (mRS) score \\>2. 2. Factors in the target vessel that are expected to prevent completion of endovascular treatment.\n\n  3\\. Concurrent anterior and posterior circulation strokes or multivessel occlusions.\n\n  4\\. Significant mass effect with imaging or clinical signs of obstructive hydrocephalus or tonsillar herniation.\n\n  5\\. Basilar artery occlusion confirmed as chronic by prior imaging or investigator judgment.\n\n  6\\. Presence of untreated intracranial aneurysms, intracranial tumors (except small meningiomas), or intracranial vascular malformations.\n\n  7\\. Intracranial hemorrhage within the past 6 months, including parenchymal brain hemorrhage, intraventricular hemorrhage, or subarachnoid hemorrhage.\n\n  8\\. Presence of active bleeding, coagulation disorders, or uncorrectable bleeding tendencies.\n\n  9\\. Severe heart, liver, or kidney dysfunction or other severe systemic late-stage diseases.\n\n  10\\. Known allergy to iodine contrast agents or other treatment-related drugs. 11. Medically uncontrolled refractory hypertension (defined as persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg) (Note: Participants can be included if their blood pressure is controllable with medication and maintained at an acceptable level).\n\n  12\\. Uncontrollable blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL. 13. Pregnancy or breastfeeding. 14. Life expectancy \\\u003C6 months. 15. Participation in other clinical studies that may affect outcome assessment. 16. Investigator's judgment that the patient is unsuitable for participation in this study or may face significant risks (e.g., due to mental illness, cognitive, or emotional disorders preventing understanding and\u002For compliance with study procedures and\u002For follow-up).",{"count":213,"type":20},348,[23],"A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial designed to evaluate the efficacy and safety of best medical management (BMM) combined with endovascular treatment (EVT) versus BMM alone in acute basilar artery occlusion (BAO) patients with large infarct cores.",[27,28,196,217],"Endovascular Treatments",[27,219,220],"Endovascular treatment","Large infarct core","2025-07-21",{"date":223,"type":39},"2025-07-29",{"date":225,"type":20},"2025-08-01",{"date":96,"type":20},{"name":228,"class":229},"The First Affiliated Hospital of Hainan Medical University","OTHER_GOV",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":21,"phases":241,"briefSummary":242,"conditions":243,"keywords":244,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":251,"leadSponsor":253,"locationsCount":73},"100596502","basilar-artery-occlusion-chinese-endovascular-trial-in-patients-with-large-core-infarct-100596502","NCT07046299","Basilar Artery Occlusion Chinese Endovascular Trial in Patients With Large Core Infarct","Safety and Efficacy of Endovascular Therapy for Acute Basilar Artery Occlusion With Large Core Infarct: A Prospective, Multicenter, Randomized, Open-Label Controlled Trial","BAOCHE3","Inclusion Criteria:\n\n1. Posterior circulation acute ischemic stroke within 24 hours from symptom onset\u002Flast seen well.\n2. Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA\u002FMRA\u002FDSA.\n3. Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 3-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.\n4. Age ≥18 and ≤80 years.\n5. Baseline NIHSS score ≥6 at the time of randomization.\n6. No significant pre-stroke functional disability (modified Rankin Scale, mRS ≤ 1).\n7. Informed consent obtained from patient or acceptable patient surrogate.\n\nExclusion Criteria:\n\nClinical exclusion criteria:\n\n1. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \\> 3.0.\n2. Baseline platelet count \\\u003C 50000\u002FµL.\n3. Baseline blood glucose of \\\u003C 50mg\u002FdL or \\>400mg\u002FdL.\n4. Severe, sustained hypertension (SBP \\> 220 mm Hg or DBP \\> 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained below these levels using commonly used medications in China for these purposes (including iv antihypertensive drips), the patient can be enrolled.\n5. Patients in whom baseline NIHSS can not be obtained by a neurologist or emergency physician prior to sedation or intubation.\n6. Seizures at stroke onset which would preclude obtaining a baseline NIHSS.\n7. Serious, advanced, or terminal illness with anticipated life expectancy of less than one year.\n8. History of life threatening allergy (more than rash) to contrast medium.\n9. Patients with acute stroke within the first 48 hours after percutaneous cardiac, cerebrovascular interventions and major surgery .\n10. Renal insufficiency with creatinine ≥ 3 mg\u002FdL.\n11. Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.\n12. Subject participating in a study involving an investigational drug or device that would impact this study.\n13. Known diagnosis or clinical suspicion of cerebral vasculitis.\n14. Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations.\n15. Unlikely to be available for 90 days follow-up (e.g. no fixed home address, visitor from overseas).\n\n    Neuroimaging exclusion criteria:\n16. Pons-midbrain-index of ≥ 4 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.\n17. CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).\n18. Complete cerebellar infarct on CT or MRI with significant mass effect and compression of the fourth ventricle.\n19. Complete bilateral thalamic infarction on CT or MRI.\n20. Evidence of vertebral occlusion, high grade stenosis or arterial dissection in the extracranial or intracranial segment that cannot be treated or will prevent access to the intracranial clot or excessive tortuosity of cervical vessels precluding device delivery\u002Fdeployment.\n21. Subjects with occlusions in both anterior and posterior circulation.\n22. Evidence of intracranial tumor (except small meningioma).","80 Years",{"count":240,"type":20},314,[23],"This study evaluates the safety and efficacy of endovascular therapy for acute basilar artery occlusion with large core infarcts in a multicenter randomized trial.",[27,195,196],[245,196,246],"Endovascular Therapy","Randomized Controlled Trial","2025-06-29",{"date":249,"type":39},"2025-07-01",{"date":249,"type":20},{"date":252,"type":20},"2028-11-30",{"name":254,"class":46},"Capital Medical University",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":21,"phases":264,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":73},"100580903","trial-of-rescue-endovascular-treatment-for-progressive-acute-mild-ischemic-stroke-with-basilar-artery-occlusion-with-extended-time-window-100580903","NCT06843356","Trial of Rescue Endovascular Treatment for Progressive Acute Mild Ischemic Stroke With Basilar Artery Occlusion With Extended Time Window","RESCUE-BAO","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Symptoms and signs consistent with basilar artery ischemia.\n3. Basilar artery or vertebral artery occlusion confirmed by computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA); if vertebral artery occlusion is present, it should completely block blood flow along the basilar artery.\n4. First-time onset meeting the criteria for mild ischemic stroke diagnosis: NIHSS score \\\u003C6.\n5. Symptom progression within 7 days of the first onset.\n6. Symptom progression: NIHSS score increase ≥4 points or consciousness level increase ≥2 points from the initial NIHSS score.\n7. Time from symptom onset to randomization \\>24 hours.\n8. Symptom progression to randomization time ≤24 hours.\n9. NIHSS score ≥10 before randomization.\n10. pc-ASPECTS before randomization ≥ 6\n11. The patient or their family members are willing to comply with the protocol requirements and data collection procedures, understand, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Symptom progression due to intracranial hemorrhage, brain edema, or other clear causes (including but not limited to infarct hemorrhagic transformation, new infarction in non-occluded vascular regions, severe infection, high fever, heart or kidney dysfunction, hypovolemia, or severe electrolyte disturbances).\n2. mRS \\>2.\n3. Factors in the target vessel that are expected to prevent completion of endovascular treatment.\n4. Multiple vessel occlusions.\n5. Prior imaging confirmed or investigator-assessed chronic basilar artery occlusion.\n6. Presence of untreated intracranial aneurysms, intracranial tumors (except small meningiomas), or intracranial vascular malformations.\n7. Intracranial hemorrhage within the past 6 months, including parenchymal brain hemorrhage, intraventricular hemorrhage, or subarachnoid hemorrhage.\n8. Gastrointestinal or urinary tract bleeding, acute myocardial infarction, cranial trauma, or major surgery within the past month.\n9. Presence of active bleeding, coagulation disorders, or uncorrectable bleeding tendencies.\n10. Platelet count \\\u003C40×10\\^9\u002FL, or INR \\>2 during anticoagulation therapy (irreversible).\n11. Severe heart, liver, or kidney dysfunction or other severe systemic late-stage diseases.\n12. Known allergy to iodine contrast agents or other treatment-related drugs.\n13. Medically uncontrolled refractory hypertension (defined as persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg) (Note: Participants can be included if their blood pressure is controllable with medication and maintained at an acceptable level).\n14. Uncontrollable blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL.\n15. Pregnancy or breastfeeding.\n16. Life expectancy \\\u003C6 months.\n17. Participation in other clinical studies that may affect outcome assessment.\n18. Investigator's judgment that the patient is unsuitable for participation in this study or may face significant risks (e.g., due to mental illness, cognitive, or emotional disorders preventing understanding and\u002For compliance with study procedures and\u002For follow-up).",{"count":263,"type":20},159,[23],"A prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial to evaluate whether best medical management (BMM) combined with endovascular therapy (EVT) improves neurological outcomes compared to BMM alone in patients with progressive acute mild ischemic stroke due to basilar artery occlusion within an extended time window.",[267,27,268,88],"Acute Mild Ischemic Stroke","Rescue Endovascular Treatment","2025-04-13",{"date":271,"type":39},"2025-04-15",{"date":273,"type":39},"2024-06-01",{"date":275,"type":20},"2026-12-31",{"name":277,"class":46},"First Affiliated Hospital of Wannan Medical College",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":238,"enrollmentInfo":286,"targetDuration":4,"studyType":21,"phases":288,"briefSummary":289,"conditions":290,"keywords":291,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":297,"leadSponsor":298,"locationsCount":73},"100559136","basilar-artery-occlusion-chinese-endovascular-trial-in-the-extended-time-window-100559136","NCT06560203","Basilar Artery Occlusion Chinese Endovascular Trial in the Extended Time Window","Safety and Efficacy of Endovascular Treatment for Acute Basilar Artery Occlusion in the Extended Time Window -a Prospective, Multicenter, Randomized Controlled, Open-label Clinical Trial","BAOCHE2","Inclusion Criteria:\n\n1. Posterior circulation acute ischemic stroke within 24-72 hours from symptom onset\u002Flast seen well (except for isolated vertigo), where patient is ineligible for IV thrombolytic treatment or the treatment is contraindicated (e.g., patient presents beyond recommended time from symptom onset), or where patient has received IV thrombolytic therapy without recanalization.\n2. Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA\u002FMRA\u002FDSA.\n3. Age ≥18 and ≤ 80.\n4. Baseline NIHSS score obtained prior to randomization must be equal or higher than 6 points.\n5. No significant pre-stroke functional disability (mRS ≤ 1).\n6. Patient treatable within 72 hours of symptom onset. Symptom onset is defined as the point in time the patient was last seen well (at baseline) if patients are unable to provide a reliable history or the point in time when symptoms have started if patients can provide a reliable history.\n7. Informed consent obtained from patient or authorized patient surrogate\n\nExclusion Criteria:\n\nClinical criteria\n\n1. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \\> 3.0.\n2. Baseline platelet count \\\u003C 50000\u002FµL.\n3. Baseline blood glucose of \\\u003C 50mg\u002FdL or \\>400mg\u002Fdl.\n4. Severe, sustained hypertension (SBP \\> 220 mm Hg or DBP \\> 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained below these levels using commonly used medications in China for these purposes (including iv antihypertensive drips), the patient can be enrolled.\n5. Patients in whom baseline NIHSS can not be obtained by a neurologist or emergency physician prior to sedation or intubation.\n6. Seizures at stroke onset which would preclude obtaining a baseline NIHSS.\n7. Serious, advanced, or terminal illness with anticipated life expectancy of less than one year.\n8. History of life threatening allergy (more than rash) to contrast medium.\n9. Patients with acute stroke within the first 48 hours after percutaneous cardiac, cerebrovascular interventions and major surgery .\n10. Renal insufficiency with creatinine ≥ 3 mg\u002Fdl.\n11. Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.\n12. Subject participating in a study involving an investigational drug or device that would impact this study.\n13. Known diagnosis or clinical suspicion of cerebral vasculitis.\n14. Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations. This excludes patients who are severely demented, require constant assistance in a nursing home type setting or who live at home but are not fully independent in activities of daily living (toileting, dressing, eating, cooking and preparing meals, etc.).\n15. Unlikely to be available for 90 days follow-up (e.g. no fixed home address, visitor from overseas).\n16. Any other condition that, in the opinion of the investigator will pose a significant hazard to the subject if participating in the trial.\n\n    Neuroimaging criteria\n17. Hypodensity with a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) \\\u003C 6 and Pons-midbrain-index of ≥ 3 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.\n18. CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).\n19. Complete cerebellar infarct on CT or MRI with significant mass effect and compression of the fourth ventricle.\n20. Complete bilateral thalamic infarction on CT or MRI.\n21. Evidence of vertebral occlusion, high grade stenosis or arterial dissection in the extracranial or intracranial segment that cannot be treated or will prevent access to the intracranial clot or excessive tortuosity of cervical vessels precluding device delivery\u002Fdeployment.\n22. Subjects with occlusions in both anterior and posterior circulation.\n23. Evidence of intracranial tumor (except small meningioma).",{"count":287,"type":20},309,[23],"A prospective, multi-center, randomized, controlled, open-label, blinded-endpoint trial to evaluate the safety and efficacy of endovascular mechanical thrombectomy for acute basilar artery occlusion in the extended time window",[26,27],[32,292],"Extended time window","2024-09-10",{"date":295,"type":39},"2024-09-19",{"date":293,"type":39},{"date":36,"type":20},{"name":254,"class":46},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":21,"phases":308,"briefSummary":310,"conditions":311,"keywords":313,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":4},"100553733","early-phase-1-cerebrolysin-as-an-add-on-therapy-to-standard-treatment-of-basilar-artery-occlusion-100553733","NCT06489925","Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion","Cerebrolysin as an Add-On Therapy to Standard Treatment of Posterior Circulation Stroke Secondary to Basilar Artery Occlusion","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Acute basilar artery occlusion confirmed on MSCT\u002F MR angiography\n* Premorbid mRS ≤ 3\n* Signed written consent\n\nExclusion Criteria:\n\n* Hypersensitivity to one of the components of the drug\n* Breastfeeding and pregnancy\n* Epilepsy, epileptic seizure\n* Severe renal impairment (grade IV and V)\n* Ischemic stroke in the previous three months\n* Metastatic cancer\n* Sepsis or a severe infection on admission\n* Acute coronary syndrome, pulmonary embolism, and deep venous thrombosis on admission",{"count":307,"type":20},20,[309],"EARLY_PHASE1","The standard therapy for acute ischemic posterior circulation stroke (PCS) often leads to poor functional outcomes and high mortality rates, despite all advances in reperfusion therapy. Recent trials have shown that adding Cerebrolysin, a cerebral neuroprotective agent, to standard therapy for patients with acute ischemic anterior circulation stroke is safe and leads to improved functional outcomes. The purpose of this study is to assess the effectiveness and safety of Cerebrolysin with standard treatment for patients with PCS secondary to basilar artery occlusion (BAO).\n\nThe plan is to conduct a prospective, single-center, single-arm, open-label study with 20 acute basilar artery occlusion patients and premorbid modified Rankin Score (mRS) ≤3, treated with standard treatment (mechanical thrombectomy ± intravenous alteplase or conservative treatment) and Cerebrolysin as add-on therapy, compared with historical controls. Besides standard acute stroke assessment, standard treatment, and rehabilitation, the participants who meet the eligibility criteria will receive Cerebrolysin in a single-day dosage of 30 ml intravenously for 14 consecutive days. The participants will be closely monitored, and neuroimaging findings and clinical outcomes will be obtained during the drug administration period, on discharge, one month, and 3 months after the treatment onset.\n\nThe primary endpoints are mRS (0-3) on day 90 and mortality rate 90 days after the stroke onset. The secondary endpoints are defined as a change in any type of intracerebral bleeding and a change of min. 2 points on the National Institutes of Health Stroke Scale 24 hours, 14 days, 30 days, and 90 days post-stroke.\n\nThe investigators hypothesize that adding Cerebrolysin to standard stroke treatment will improve clinical outcomes and reduce morbidity and mortality in patients with acute basilar occlusion compared to standard treatment alone.",[27,312],"Posterior Circulation Brain Infarction",[314,315,115,316,317],"Cerebrolysin","neuroprotection","add-on therapy","posterior circulation stroke","2024-07-08",{"date":320,"type":39},"2024-07-09",{"date":322,"type":20},"2024-07",{"date":324,"type":20},"2026-05",{"name":326,"class":46},"University Hospital Sestre Milosrdnice",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":21,"phases":337,"briefSummary":338,"conditions":339,"keywords":340,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":350},"100463866","contact-aspiration-versus-stent-retriever-for-recanalisation-of-acute-stroke-patients-with-basilar-artery-occlusion-the-posterior-circulation-aster-randomized-trial-protocol-100463866","NCT05320263","Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial Protocol","Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial","pc-ASTER","Inclusion Criteria:\n\nAge ≥ 18 years\n\n* AIS with BAO on non-invasive imaging (CT or MRI)\n* Eligible for thrombectomy : groin puncture undergone within 24 hours of first symptoms or of last time the patient was seen normal\n* Being covered by a national health insurance\n* Informed consent obtained from the patients\u002Fhis proxy or following an emergency procedure\n\nExclusion Criteria:\n\n* Known or suspected pre-existing (chronic) large vessel stenosis \u002F occlusion in the symptomatic territory (basilar artery)\n* Severe contrast medium allergy or absolute contraindication to use of iodinated products\n* Clinical history, past imaging or clinical judgment suggesting intracranial stenosis of the basilar artery\n* Pregnancy (urine or serum beta HCG test for women of child-bearing potential)\n* Person deprived of liberty\n* Patient benefiting from a legal protection (guardianship or curatorship)",{"count":336,"type":20},480,[23],"Acute ischemic stroke (AIS) patients with basilar artery occlusion (BAO) present a devastating, life-threatening prognosis.\n\nUrgent recanalization with endovascular mechanical thrombectomy is routinely performed in patients with BAO although the level of evidence is lower than that in anterior circulation occlusions (randomization in this population versus medical treatment alone having been impossible in recent studies). Recently, a large retrospective study supports the interest of thrombectomy in this population .\n\nSpeed and grade of the recanalisation have a major impact on clinical outcome. Favorable outcome at 90 days is strongly associated with the successful recanalization status at the end of the endovascular procedure (OR=4.57, 95%CI=1.24-16.87, P=0.023).\n\nFirst pass effect has been shown to be a strong marker of efficacy of endovascular procedure with significant correlation with clinical outcome.\n\nThrombectomy with Stent retrievers dramatically changed the prognosis of anterior circulation large vessel occlusion strokes and currently used in BAO patients (posterior circulation). Contact aspiration (CA) is currently used in anterior large vessel occlusions (COMPASS trial, Lancet 2019), with similar rates of recanalization and favorable outcomes (Boulanger M, 2019), as well as in BAO patients .\n\nHowever, the benefit of CA compared to SR for the treatment of BAO remains under debate with the superiority of first line CA compared to SR or no difference. Available data are based on retrospective studies with no data from RCT.\n\nIn this context, a randomized controlled trial is needed to assess the benefit of CA versus SR.",[27],[116,30],"2023-02-27",{"date":343,"type":39},"2023-03-01",{"date":345,"type":39},"2022-11-19",{"date":347,"type":20},"2027-07",{"name":349,"class":46},"Hopital Foch",12]